Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/341579
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampDelamain, Marcia Torresan-
dc.contributor.authorunicampDuarte, Gislaine Oliveira-
dc.contributor.authorunicampZulli, Roberto-
dc.contributor.authorunicampSouza, Carmino Antonio de-
dc.contributor.authorunicampLorand-Metze, Irene-
dc.contributor.authorunicampPagnano, Katia Borgia Barbosa-
dc.typeArtigopt_BR
dc.titleEvaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phasept_BR
dc.contributor.authorMoura, M.S.-
dc.contributor.authorBenevides, T.C.L.-
dc.contributor.authorDelamain, M.T.-
dc.contributor.authorDuarte, G.O.-
dc.contributor.authorPercout, P.O.-
dc.contributor.authorDias, M.A.-
dc.contributor.authorZulli, R.-
dc.contributor.authorSouza, C.A.D.-
dc.contributor.authorLorand-Metze, I.-
dc.contributor.authorPagnano, K.B.B.-
dc.subjectLeucemia mielóide crônicapt_BR
dc.subject.otherlanguageChronic myeloid leukemiapt_BR
dc.description.abstractIntroduction: The incidence of grade 3–4 anemia was reported to be 3% with imatinib therapy for newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). However, there are few data regarding the causes and the development of anemia after long-term treatment. This study aimed to evaluate the incidence of anemia after at least two years of imatinib treatment of CML patients in the CP and to identify other contributing causes of anemia in this population. Patients and methods: We performed a retrospective analysis of 97 CML patients in the CP treated with imatinib for at least two years. We analyzed the hemoglobin (Hb) levels of CML patients at diagnosis, upon initiation of treatment with imatinib and after two years of imatinib treatment, and investigated other causes of anemia in this population. Results: Most of the patients presented Hb levels below the normal range (80.4%) after the second year of treatment, 17.9% grade 2 and 1.3% grade 3. In 13 cases (16.7%), anemia was attributed to resistance and in 13 cases (16.7%) the following causes were identified: iron deficiency (n = 5), hypothyroidism (n = 2), vitamin B12 deficiency (n = 3), acquired immune deficiency syndrome (AIDS) (n = 1), pulmonary tuberculosis (n = 1) and renal toxicity (n = 1). In 52 patients (66.6%), there were no other factors contributing to anemia, except imatinib treatment. Conclusion: Regular follow-up is required to identify the causes of anemia not related to CML or imatinib toxicity. The importance of investigating secondary causes of anemia should be emphasized, especially in patients with good adherence to treatment and satisfactory therapeutic responsept_BR
dc.relation.ispartofHematology, transfusion and cell therapypt_BR
dc.publisher.citySão Paulo, SPpt_BR
dc.publisher.countryBrasilpt_BR
dc.publisherElsevierpt_BR
dc.date.issued2019-
dc.date.monthofcirculationOct./Dec.pt_BR
dc.language.isoengpt_BR
dc.description.volume41pt_BR
dc.description.issuenumber4pt_BR
dc.description.firstpage329pt_BR
dc.description.lastpage334pt_BR
dc.rightsFechadopt_BR
dc.sourceSCOPUSpt_BR
dc.identifier.issn2531-1379pt_BR
dc.identifier.eissn2531-1387pt_BR
dc.identifier.doi10.1016/j.htct.2019.03.006pt_BR
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S2531137919300896pt_BR
dc.description.sponsordocumentnumbersem informaçãopt_BR
dc.date.available2020-05-16T14:09:42Z-
dc.date.accessioned2020-05-16T14:09:42Z-
dc.description.provenanceSubmitted by Sanches Olivia (olivias@unicamp.br) on 2020-05-16T14:09:42Z No. of bitstreams: 0. Added 1 bitstream(s) on 2020-08-27T19:15:11Z : No. of bitstreams: 1 2-s2.0-85074120534.pdf: 451450 bytes, checksum: b5ec6e2d535d8b10d93b9b4f1f5a1577 (MD5)en
dc.description.provenanceMade available in DSpace on 2020-05-16T14:09:42Z (GMT). No. of bitstreams: 0 Previous issue date: 2019en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/341579-
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentDepartamento de Clínica Médicapt_BR
dc.contributor.departmentDepartamento de Clínica Médica |pt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeCentro de Hematologia e Hemoterapiapt_BR
dc.contributor.unidadeCentro de Hematologia e Hemoterapiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeCentro de Hematologia e Hemoterapiapt_BR
dc.subject.keywordImatinibpt_BR
dc.subject.keywordAnemiapt_BR
dc.subject.keywordAdverse eventspt_BR
dc.identifier.source2-s2.0-85074120534pt_BR
dc.creator.orcid0000-0001-9071-4397pt_BR
dc.creator.orcidsem informaçãopt_BR
dc.creator.orcid0000-0003-1060-7183pt_BR
dc.creator.orcid0000-0001-8656-8374pt_BR
dc.creator.orcid0000-0002-6516-1265pt_BR
dc.creator.orcidsem informaçãopt_BR
dc.type.formArtigo originalpt_BR
dc.description.otherSponsorshipsem informaçãopt_BR
Appears in Collections:FCM - Artigos e Outros Documentos
HEMO - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-85074120534.pdf440.87 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.